Particle.news

Blood Biomarker Linked to Advanced CTE in Two JAMA Studies

Researchers say elevated eMTBR-tau in blood could allow diagnosis during life if larger studies confirm the finding and its separation from Alzheimer’s pathology.

Overview

  • Two independent papers in JAMA report elevated measures of eMTBR-related tau in people with autopsy-confirmed, late‑stage chronic traumatic encephalopathy, with one Boston University/Banner Health case series of 21 former football players showing higher eMTBR-tau in CTE-positive participants.
  • In the BU case series, autopsies found CTE in 18 of 21 donors and 16 had high-stage disease, and statistical analysis showed significantly higher eMTBR-tau in high-stage CTE than in low-stage or no CTE.
  • Both studies note that eMTBR-tau and the fragment eMTBR-tau243 track tau tangles also seen in Alzheimer’s disease, and levels were highest when Alzheimer’s copathology was present, raising questions about test specificity.
  • Authors and editorialists emphasize the results are discovery‑phase: the samples were small, lacked age-matched controls, were mostly white, and the blood tests are not FDA‑approved or ready for clinical diagnosis.
  • Next steps include larger, more diverse validation studies and multi-site efforts such as DIAGNOSE CTE to confirm accuracy, separate CTE from Alzheimer’s signals, and determine whether the marker can be used to enroll and monitor clinical trials.